logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2H 2019
MediWound Ltd.
submission of BLA for NexoBrid
Burn patients
2H 2019
Ironwood Pharmaceuticals, Inc.
Data from Phase 1 study of IW-6463
Serious and orphan CNS disorders
2H 2019
Curis Inc
Initial efficacy data from phase I trial of CA-170 in the U.S.
Advanced solid tumors and lymphomas
2H 2019
Novus Therapeutics, Inc.
Data from new phase IIa trial of OP0201
Acute otitis media in infants and children
2H 2019
Aileron Therapeutics, Inc.
Preliminary data from phase IIa expansion cohort of ALRN-6924 in combination with IBRANCE
Cancer patients with MDM2-amplified solid tumors
2H 2019
Replimune Group Inc.
Data from full Phase 1 part of Phase 1/2 study of RP1
solid tumors
2H 2019
Replimune Group Inc.
Data from full Phase 1 part of Phase 1/2 study of RP1 combined with Opdivo
solid tumors
2H 2019
Constellation Pharmaceuticals, Inc.
Interim phase II data of CPI-1205 (ProSTAR)
Metastatic castration-resistant prostate cancer (mCRPC)
2H 2019
TCR2 Therapeutics
Clinical data from phase 1/2 clinical trial of TC-210
Mesothelin-positive solid tumors
2H 2019
TCR2 Therapeutics
Filing of IND for TC-110
Ovarian cancer
2H 2019
G1 Therapeutics, Inc.
Additional data from phase Ib clinical trial of Lerociclib/Faslodex
ER+, HER2- breast cancer
2H 2019
G1 Therapeutics, Inc.
Preliminary dose-escalation data from phase Ib clinical trial of Lerociclib/Tagrisso
Non-small cell lung cancer
2H 2019
G1 Therapeutics, Inc.
Preliminary dose-escalation data from phase I clinical trial of G1T48
ER+ breast cancer
2H 2019
Aldeyra Therapeutics, Inc.
Results from phase III clinical trial of 0.5% topical ocular Reproxalap(SOLACE)
Noninfectious anterior uveitis
2H 2019
Aldeyra Therapeutics, Inc.
Results from Part 1 of a phase III clinical trial of 1% topical dermal Reproxalap(RESET)
Ichthyosis associated with Sjögren-Larsson Syndrome
Jul 2019
BioPharmX Corp
Top-line data from phase IIb clinical trial of BPX-041
Papulopustular rosacea
2H 2019
Syndax Pharma
Initial results from phase I dose escalation trial of SNDX-6352
Chronic graft versus host disease (cGVHD)
2H 2019
Supernus Pharmaceuticals, Inc.
Submission of NDA for SPN-812
Attention-Deficit-Hyperactivity Disorder
2H 2019
Unum Therapeutics Inc.
Additional data from phase I trial of ACTR087 in combination with SEA-BCMA (ATTCK-17-01)
Relapsed or refractory Multiple Myeloma
Q3 2019
DBV Technologies S.A. -
Resubmission of BLA for Viaskin Peanut
Peanut allergy
2H 2019
INmune Bio Inc.
Initial data from phase I portion of phase I/II study of INKmune
Relapse refractory ovarian cancer in women
Q3 2019
Aravive, Inc.
Interim safety, pharmacodynamic, and pharmacokinetic data for Phase 1b portion of Phase 1b/2 clinical trial of AVB-S6-500
Platinum-resistant recurrent ovarian cancer
2H 2019
Evelo Biosciences, Inc.
Topline data from phase 1b trial of EDP1815 6
Atopic Dermatitis or Psoriasis
2H 2019
MacroGenics Inc.
Submisson of BLA for Margetuximab
HER2-positive metastatic breast cancer
Jul 2019
Neon Therapeutics, Inc.
Top-line clinical results from phase Ib trial of NEO-PV-01 and Opdivo
Metastatic or advanced melanoma, lung, or bladder cancer